zenner patrick j  insider stock trading  openinsider sector all sectors group by sector aerospace agriculture automobile building business services chemical electrical energy fashion financial food  beverage fund healthcare household insurance machinery media metals mining other personal services real estate retail technology telecom transportation utility industry all industries group by industry insiders filings all purchases sales cik   address co selecta biosciences inc  arsenal way watertown ma   results links secyahoogooglefinviztradingviewstockchartsstocktwitsdownload csv tc stat stk ins fil d w m q h y avg pretpwinssretswins filing date t date ticker issuerinc sector indindustry owner ost rel title t tval price l qty oc own h ry ry rm rm rw rw rd rd fd fw fm fm fm fy  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadpd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadsdd  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpi  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpi  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadsdd  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpi  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpi  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadsdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadsdd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdd  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpi  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpd  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpd  arqlarqule incdehealthdrugpharmaceutical preparationszenner patrick jmadpnewd  scrxsciele pharma incdehealthdrugpharmaceutical preparationszenner patrick jgadpi  crgncuragen corpdehealthbiolabcommercial physical  biologizenner patrick jctdpnewd  wstwest pharmaceutical services incpahshldplprdfabricated rubber productszenner patrick jpadmdnewd  scrxsciele pharma incdehealthdrugpharmaceutical preparationszenner patrick jgadsi  drtedendrite international incnjtechsoftwprepackaged softwarezenner patrick jnjdmdd  drtedendrite international incnjtechsoftwprepackaged softwarezenner patrick jnjdmdd dderivative transaction in filing usually option exercise mmultiple transactions in filing earliest reported transaction date and weighted average transaction price aamended filing eerror detected in filing s  salesale of securities on an exchange or to another person s  saleoesale of securities on an exchange or to another person after option exercise f  taxpayment of exercise price or tax liability using portion of securities received from the company p  purchasepurchase of securities on an exchange or from another person return to top contact copyright   openinsidercom all rights reserved patrick zenner  arqule  inc  zoominfocompatrick j zenner chmn arqule inc a publisher of business information since         search business search executive   advanced search   sign in    hints profile of patrick zenner   patrick zenner   chmn  arqule inc   patrick zenner email  please login   company name  arqule inc   company website  wwwarqulecom   company address   presidential way woburn maunited states   patrick zenner profile  chmn  arqule inc   patrick zenner biography  patrick j zenner was named chairman of the board in may  and has been a director since  a year veteran of the pharmaceutical industry patrick zenner retired in  from the position of president and chief executive officer of hoffmannla roche inc north america hoffmannla roche inc based in nutley nj is the prescription drug unit of the roche group mr zenner is currently on the board of trustees of creighton university and is chairman of the board of trustees of fairleigh dickinson university in addition mr zenner is a member on the boards of directors of curagen corporation praecis pharmaceuticals inc geron corporation sciele pharma inc xoma ltd west pharmaceutical services and exact sciences inc   patrick zenner colleagues  name title email werner cautreels member  scientific advisory board please login william messenger board dir please login ronald lindsay board dir please login timothy barabe board dir please login anthony messina vp  human development please login             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory        walkerss research  a publisher of business information since  all rights reserved wst patrick j zenner insider trades for west pharmaceutical services inc bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close west pharmaceutical services inc nyse wst go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus west pharmaceutical services inc after hours  quotes are delayed by  min jul    pm wst quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual patrick j zenner mr patrick j zenner is nonexecutive chairman at west pharmaceutical services inc chairman at arqule inc and chairman at fairleigh dickinson university he is on the board of directors at healthcare institute of new jersey biotechnology industry organization creighton university and pharmaceutical research  manufacturers of america mr zenner was previously employed as independent director by par pharmaceutical cos inc chairman by exact sciences corp president  chief executive officer by hoffmannla roche inc vice president  general manager by roche laboratories inc and president  chief executive officer by roche holdings inc he also served on the board at sciele pharma inc xoma ltd curagen corp dendrite international inc geron corp endotis pharma sarl neurod sa nextwave pharmaceuticals inc and praecis pharmaceuticals inc he received his undergraduate degree from creighton university and an mba from fairleigh dickinson university transactions date shares transaction value     award at  per share      award at  per share      gift at  per share      acquisition at  per share      award at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr patrick j zenner nonexecutive chairman mr eric mark green president chief executive officer  director mr david a montecalvo svpglobal operations  supply chain mr william j federici chief financial officer  senior vice president mr eric resnick chief technology officer  vice president mr patrick a sim chief information officer  vice president mr donald a mcmillan vice presidententerprise business systems mr chris ryan vice president  general managerglobal generics mr mike schaefers vice presidentproduct management dr scott young vice presidentprimary container technology mr graham s reynolds vice president  general managerglobal biologics mr mike treadaway vp  general managercontract manufacturing ms karen a flynn chief commercial officer  senior vice president mr heino lennartz vice president  general managerglobal pharma mr paolo pucci director ms erin o’brien senior directormarketing mr daniel malone vice president  controller dr quintin john lai vice presidentcorporate development  strategy ms emily y denney headglobal communications ms annette f favorite chief human resources officer  senior vp mr george lloyd miller secretary senior vice president  general counsel ms deborah l keller independent director mr john h weiland independent director dr myla p laigoldman independent director dr william f feehery independent director mr douglas a michels independent director mr mark a buthman independent director dr paula a johnson independent director mr thomas w hofmann independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest abreakingelon musk details tesla model  pricing range atesla standard model  will cost  longrange model will cost  pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  selecta announces addition of patrick j zenner to board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       selecta selb announces addition of patrick j zenner to board of directors tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs watertown mass june   globe newswire  selecta biosciences inc nasdaqselb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the election of patrick j zenner to its board of directors at the company’s  annual meeting of stockholders which was held on june   mr zenner previously served as president and chief executive officer of hoffmannla roche inc north america the prescription drug unit of roche “i am delighted that we were able to add an executive of patrick’s caliber to selecta’s board of directors” said werner cautreels phd ceo and chairman of selecta “we believe his experience in leading an expanding organization navigating regulatory hurdles and commercializing a range of major therapeutics will be key as we seek to advance our clinical programs and enable new treatments using our synthetic vaccine particles svp™ technology platform” prior to his retirement mr zenner held various positions during his year career at roche he currently serves as chairman of the boards of directors of both arqule inc and west pharmaceutical services inc previously mr zenner served as a director of par pharmaceuticals and several other public and private company boards he received his bsba from creighton university and his mba from fairleigh dickinson university about selecta biosciences incselecta biosciences inc is a clinicalstage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses selecta plans to combine its tolerogenic synthetic vaccine particles svp™ to a range of biologics for rare and serious diseases that require new treatment options the company’s current proprietary pipeline includes svpenabled enzyme oncology and gene therapies sel the company’s lead candidate in phase  is being developed to treat severe gout patients and resolve their debilitating symptoms including flares and gouty arthritis selecta’s clinical oncology candidate lmb is in a phase  program targeting pancreatic cancer and mesothelioma its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration the use of svp is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases selecta is based in watertown massachusetts for more information please visit httpselectabiocom and follow selectabio on twitter forwardlooking statements any statements in this press release about the future expectations plans and prospects of selecta biosciences inc “the company” including without limitation the company’s ability to unlock the full potential of biologic therapies the company’s plan to apply its svp platform to a range of biologics for rare and serious diseases the potential of sel to treat severe gout patients and resolve their debilitating symptoms the potential of the company’s two gene therapy product candidates to enable repeat administration the potential treatment applications for products utilizing the svp platform in areas such as gene therapy immunooncology allergies autoimmune diseases and vaccines and other statements containing the words “anticipate” “believe” “continue” “could” “estimate” “expect” “hypothesize” “intend” “may” “plan” “potential” “predict” “project” “should” “target” “would” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors discussed in the “risk factors” section of the company’s quarterly report on form q filed with the securities and exchange commission or sec on may   and in other filings that the company makes with the sec in addition any forwardlooking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date the company specifically disclaims any obligation to update any forwardlooking statements included in this press release contact information jason fredette selecta biosciences inc  jfredetteselectabiocom read at biospacecom related news selecta selb reports data from ongoing phase ii trial of lead candidate sel in development for chronic severe gout aziyo biologics banks some cash and former osiris osir exec as its new ceo selecta selb commences dosing in phase i clinical trial of nicotine vaccine for smoking cessation and relapse prevention effective immediately bristolmyers squibb bmy exec to take the reins at kleo lyophilization services of new england contract manufacturing announces manufacturing agreement with selecta selb what would  industry icons do differently if given the chance to be ceo again selecta selb obtains license for recombinant immunotoxin lmb from nci for pancreatic cancer mesothelioma and other cancers alexion alxn poaches biogen biibs longtime cfo selecta selb announces first quarter  financial results and provides corporate update struggling teva teva wants to overhaul board by nominating  new directors please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • selecta biosciences inc   • biotechpharma  personnel                 zenner products  water meters heat meters amrtechnology  zenner skip navigation zenner homepage  sitemap  imprint  data security  terms  conditions   sprachelanguage my es ru it deutsch ru es ru hu pt fr pl ru english english english skip navigation products » zenner product categorieswater meters heat meters amr systems » product finderfind the right product systems » bus systemsmbus and zennerbus » wireless mbus systemswalkby radio system » stationary radio systemsmart metering on the internet of things iot » stationary gsm systemgsm data logger multilog service » dial and counter types » informations on the mid » laws and regulations » product and system support company » facts and figures » zenner guidelines » certificates » company history » minolzennergroup news » press releases » video » smart  easyzenner customer magazine » calendar of events » zenner newsletter download » catalogs and brochures » installation instructions » downloadarchivedocuments for former products contact » sales international » product and system support » subsidiaries and branches » contact us countries » europe » българия bulgaria » deutschland » españa » france » magyarország » italia » luxembourg » norge » österreich » polska » portugal » россия russia » schweiz » slovenija » türkiye » united kingdom » north  middleamerica » mexico » united states » south america » brasil » colombia » paraguay » otros paísesecuador el salvador peru » middleeast » asia  australia » australia » china » india » thailand » vietnam » africa » africa  english speaking countriesegypt ethiopia libya south africa » afrique  pays francophonealgérie côte divoire cameroun congo maroc senegal tunisie » áfrica  países de língua portuguêsmoçambique angola são tomé e cabo verde   product range zenner products in a glance download certified quality zenner international gmbh  co kg is din en iso  and din en iso  certified all zenner meters correspond to the design and connection dimensions of din iso  andor din iso  part  din en  and other national and international standards and guidelines  zenner  all that counts  zenner products  water meters heat meters amrtechnology zenner products  all that counts water meters  heat meters  gas meters  amrtechnology for over  years zenner has been one of the leading suppliers of innovative measuring technology true to our motto “all that counts” we supply our customers with a complete product portfolio of water meters gas meters heat meters and amrsystems with modular construction and extendable with the appropriate accessories and the most up to date systems technology our products are the first choice in every field of application measuring technology for homes and flats domestic industrial or municipal water supply  every customer group will find a suitable product at zenner ongoing dialog with our customers and partners makes continuous product innovation possible for us across a wide range of customer groups and market segments products by categoryin this area you´ll find all our water meters heat meters gas meters and amrsolutions sorted by product categories  more product finderthe zenner product finder helps you to find the right zenner product for your individual needs  more productsproducts by categoryproduct finderamrsystemsbussystemswireless mbus systemsstationary gsmsystemservicesdial and meter typesinformations on the midlaws and regulationstechnical support zennerfacts and figuresguidelinescertificatescorporate historyminolzennergroupnewsroompress releasesvideoscalendar of eventszenner newsletter downloadscatalogues and broschuresinstallation instructionscontactsales internationaltechnical supportinternational subsidiariescontact us countrieseuropenorth and middleamericasouthamericamiddle eastafricaothershomepagesitemapimprintterms and conditions zenner is a member of patrick j zenner  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in patrick j zenner chairman of the board at west pharmaceutical services inc view full profile are you patrick j zenner claim your profile   sign up for equilar atlas and view patrick j zenners full profile with equilar atlas you can identify corporate executives in patrick j zenners network and community follow changes in patrick j zenners employment and moneyinmotion connect with patrick j zenner through your network of contacts patrick j zenners executive work history current chairman of the board west pharmaceutical services inc past to view patrick j zenners complete executive work history sign up now education bs creighton university age      patrick j zenners biography mr zenner was named chairman of the board in may  and has been a director since  mr zenner retired in  from the position of president and chief executive officer of hoffmannla roche inc north america based in nutley nj mr zenner held various executive positions during his year career with the company mr zenner is currently a member of the board of trustees of creighton university and is chairman of the board of trustees of fairleigh dickinson university in addition mr zenner is chairman of the board of directors of west pharmaceutical services inc until its sale in  mr zenner was a director of par pharma  read more mr zenner was named chairman of the board in may  and has been a director since  mr zenner retired in  from the position of president and chief executive officer of hoffmannla roche inc north america based in nutley nj mr zenner held various executive positions during his year career with the company mr zenner is currently a member of the board of trustees of creighton university and is chairman of the board of trustees of fairleigh dickinson university in addition mr zenner is chairman of the board of directors of west pharmaceutical services inc until its sale in  mr zenner was a director of par pharmaceuticals inc in  he resigned from the boards of geron corporation xoma ltd and exact sciences inc until its sale in september  mr zenner was a director of curagen corporation he has a bsba from creighton university and an mba from fairleigh dickinson university source arqule inc on    sign up for equilar atlas and view patrick j zenners full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like patrick j zenner more specifically youll be able to identify corporate executives in patrick j zenners network and community follow changes in patrick j zenners employment and moneyinmotion connect with patrick j zenner through your network of conections view full profile   search for over  executive profiles bio example patrick j zenner patrick j zenners connections  sign up now to view patrick j zenners  connections » daniel p neary board member valmont industries inc douglas g watson former chairman of the board orasure technologies inc donald e morel board member integra lifesciences holdings corporation john h weiland dir president and chief operating officer c r bard inc john a fazio former board member heidrick  struggles international inc john n kapoor board member akorn ronald m cresswell former board member vericel corporation myla p laigoldman board member west pharmaceutical services inc david j earp former senior vice president corporate transactions geron corporation john varian dir and former chief executive officer xoma corporation popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   selecta biosciences announces addition of patrick j zenner to board of directors research stocks news story skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  news  events  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print format change text size default text sizea larger text sizea largest text sizea selecta biosciences announces addition of patrick j zenner to board of directors by globenewswire—  am et  watertown mass june   globe newswire  selecta biosciences inc selb  a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the election of patrick j zenner to its board of directors at the company’s  annual meeting of stockholders which was held on june   mr zenner previously served as president and chief executive officer of hoffmannla roche inc north america the prescription drug unit of roche “i am delighted that we were able to add an executive of patrick’s caliber to selecta’s board of directors” said werner cautreels phd ceo and chairman of selecta “we believe his experience in leading an expanding organization navigating regulatory hurdles and commercializing a range of major therapeutics will be key as we seek to advance our clinical programs and enable new treatments using our synthetic vaccine particles svp™ technology platform” prior to his retirement mr zenner held various positions during his year career at roche he currently serves as chairman of the boards of directors of both arqule inc and west pharmaceutical services inc previously mr zenner served as a director of par pharmaceuticals and several other public and private company boards he received his bsba from creighton university and his mba from fairleigh dickinson university about selecta biosciences inc selbselecta biosciences inc selb is a clinicalstage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses selecta plans to combine its tolerogenic synthetic vaccine particles svp™ to a range of biologics for rare and serious diseases that require new treatment options the company’s current proprietary pipeline includes svpenabled enzyme oncology and gene therapies sel the company’s lead candidate in phase  is being developed to treat severe gout patients and resolve their debilitating symptoms including flares and gouty arthritis selecta’s clinical oncology candidate lmb is in a phase  program targeting pancreatic cancer and mesothelioma its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration the use of svp is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases selecta is based in watertown massachusetts for more information please visit httpselectabiocom and follow selectabio on twitter forwardlooking statements any statements in this press release about the future expectations plans and prospects of selecta biosciences inc selb “the company” including without limitation the company’s ability to unlock the full potential of biologic therapies the company’s plan to apply its svp platform to a range of biologics for rare and serious diseases the potential of sel to treat severe gout patients and resolve their debilitating symptoms the potential of the company’s two gene therapy product candidates to enable repeat administration the potential treatment applications for products utilizing the svp platform in areas such as gene therapy immunooncology allergies autoimmune diseases and vaccines and other statements containing the words “anticipate” “believe” “continue” “could” “estimate” “expect” “hypothesize” “intend” “may” “plan” “potential” “predict” “project” “should” “target” “would” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors discussed in the “risk factors” section of the company’s quarterly report on form q filed with the securities and exchange commission or sec on may   and in other filings that the company makes with the sec in addition any forwardlooking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date the company specifically disclaims any obligation to update any forwardlooking statements included in this press release contact information jason fredette selecta biosciences inc selb  jfredetteselectabiocom image primary logo source selecta biosciences selb more selb news briefselecta bio provides data from midstage study testing gout drug reuters   am et  selecta biosciences reports data from ongoing phase  trial of lead candidate sel in development for chronic severe gout globenewswire   am et  briefselecta biosciences notifies spark therapeutics about license agreement reuters   pm et  copyright – fmr llc  all rights reserved  terms of use privacy security site map  stock market research top stocks quotes  news  fidelity investments skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window stock research  ideas you are here stock research center my research screen  filter stock screeners preset expert strategies news  insights events calendar upgrades  downgrades explore firm research research firms research firm scorecards reports search related resources fidelity learning center us markets global markets sectors  industries stock research center not a fidelity customer no problem try our research for free without opening an account   trending stocks market movers top rated by sector orders by fidelity customers filters refresh equity summary score provided by starmine investing insights technical events provided by recognia as of  methodology recognia methodology bullish and bearish events of the day provide longshort trading ideas by identifying us stocks that have recently formed a bullish or bearish classic chart pattern patterns must have taken at least  days to form which draws out the more significant patterns for intermediate or longterm trend direction the list is then filtered to include stocks with a minimum  for bullish and  for bearish close price and a minimum  trading volume most recent patterns are listed first patterns on the same date are sorted using recognias proprietary quantitative algorithm to draw strong companies to the top and if further sorting is required for stocks with the same quantitative analysis result it is done by trading volume to draw highest volume stocks to the top msfg log in for events vcyt boot tbbk logm jack log in for events rev gifi rdwr impv find out how to use fundamental analysis and technical analysis when evaluating stocks with the help of the fidelity learning center my research –  organize and track your favorite securities get started todays events as of  am et  earnings  dividends  splits  upgrades  downgrades  economic  upcoming webinar events visit the learning center events page for a full list of upcoming webinars the equity summary score is provided for informational purposes only does not constitute advice or guidance and is not an endorsement or recommendation for any particular security or trading strategy the equity summary score is provided by thomson reuters starmine an independent company not affiliated with fidelity investmentsgics® global industry classification standards is an industry classification system developed by standard  poors in collaboration with morgan stanley capital international msci sp uses gics to determine the market segment to which a company is assignednews commentary including related symbols and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their usestock markets especially foreign markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments sector funds can be more volatile because of their narrow concentration in a specific industrysystem availability and response times may be subject to market conditionsthe fidelity screeners are research tools provided to help selfdirected investors evaluate securities the criteria and inputs entered are at the sole discretion of the user and all screens or strategies with preselected criteria are solely for the convenience of the user information supplied or obtained from the screeners is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell securities or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy or approach to screening or evaluating stocks preferred securities exchange traded products or closed end funds fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their use determine which securities are right for you based on your investment objectives risk tolerance financial situation and other individual factors and reevaluate them on a periodic basis copyright – fmr llc  all rights reserved  terms of use privacy security site map  selb stock news  fidelity skip to main content site navigation fidelitycom home customer service open an account refer a friend log in customer service open an account refer a friend log out search fidelitycom accounts  trade portfoliolog in required account positionslog in required tradelog in required active trader prolog in required transferlog in required cash managementlog in required billpaylog in required full viewlog in required profilelog in required account featureslog in required statementslog in required tax information retirement distributionslog in required offer see our featured trading offer learn more planning  advice what we offer financial basics building savings managing  growing wealth retirement life events news  research news watch listlog in required quotes alertslog in required mutual funds stocks fixed income bonds  cds etfs options markets  sectors ipos annuities learning center notebook notebook investment products mutual funds retirement  iras trading stocks fixed income bonds  cds etfs options sector investing cash management  credit cards managed accounts fidelity go  college savings annuities life insurance  long term care why fidelity the fidelity advantage planning  advice trading straightforward pricing insights  tools security  protection customer service open an account refer a friend log in customer service open an account refer a friend log out content and data provided by various third parties and fidelity − terms of use research  stocks  stock details enter company or symbol press down arrow for suggestions or escape to return to entry field view this information for the company or symbol snapshot detailed quote adv chart  technical news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings view this information for the company or symbol snapshot detailed quote advanced chart news analyst reports find symbol opens in new window snapshot detailed quote advanced chart  technical analysis news  events compare analyst opinions research reports key statistics earnings dividends ownership  insiders financial statements sec filings related resources stock research overview stock screeners markets  sectors fidelity learning center print  helpglossary helpglossary news  eventsselb selecta biosciences inc    as of pm et  quotes delayed at least  min log in for real time quote add to watch list set alert hypothetical trade price history download to csv file download to excel file log in for more news expand all collapse all briefselecta biosciences files for offering of  mln shares by selling stockholders reuters –  am et  selecta biosciences inc selb  selecta biosciences selb files shelf prospectus relating to proposed offering and resale of  million shares of common stock by selling stockholders  sec filing source text further company coverage briefvivo capital viii reports  pct passive stake in selecta biosciences reuters –  pm et  vivo capital viii llc  vivo capital viii llc reports  percent passive stake in selecta biosciences inc selb as of june    sec filing source text briefselecta biosciences reports  mln private placement reuters –  am et  selecta biosciences inc selb  selecta biosciences selb announces  million private placement  selecta biosciences inc selb  entered agreements to sell securities in private placement that is expected to result in proceeds to company of  million  selecta biosciences inc selb  plans to use proceeds from financing primarily for ongoing clinical development of selectas lead product candidate sel selecta biosciences announces  million private placement globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced that it has entered into definitive agreements to sell securities in a private placement that is expected to result in gross proceeds to the company of  million before deducting placement agent and other of selecta biosciences announces addition of patrick j zenner to board of directors globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the election of patrick j zenner to its board of directors at the companys  annual meeting of stockholders which was held on june   briefselecta bio provides data from midstage study testing gout drug reuters –  am et  selecta biosciences inc selb  selecta biosciences selb reports data from ongoing phase  trial of lead candidate sel in development for chronic severe gout  sel generally well tolerated  reduced rate of gout flares with sel  selecta biosciences selb  majority of patients in minimum effective dose group in study maintained sua control following three monthly injections of sel selecta biosciences reports data from ongoing phase  trial of lead candidate sel in development for chronic severe gout globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced data from its ongoing phase  trial of sel which is being developed for patients with chronic severe gout briefselecta biosciences notifies spark therapeutics about license agreement reuters –  pm et  spark therapeutics inc once  selecta bioscienceson june notified spark therapeutics once license agreement would terminate as spark had not made may  license payment by may  source text  httpbitlystpqy further company coverage selecta biosciences announces upcoming clinical presentations globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the following upcoming clinical presentations annual european congress of rheumatology federation of clinical immunology societies annual meeting selecta plans to report updated patient data from its ongoing selecta biosciences to present at the jefferies global healthcare conference on june   globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced that ceo and chairman werner cautreels phd will be presenting at the jefferies  global healthcare conference in new york city at  pm et on wednesday june   selecta biosciences announces new preclinical gene therapy data at the annual meeting of the american society of gene  cell therapy asgct globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced new preclinical data regarding nonimmunogenic gene therapies that were presented at the american society of gene  cell therapy  annual meeting which took place last week in washington dc immunogenici briefselecta biosciences q loss per share  reuters –  pm et  selecta biosciences inc selb  selecta biosciences selb announces first quarter  financial results and provides corporate update  q loss per share   q revenue  versus  million source text for eikon further company coverage briefselecta biosciences commences dosing in phase  clinical trial of nicotine vaccine for smoking cessation and relapse prevention reuters –  pm et  selecta biosciences inc selb  selecta biosciences selb commences dosing in phase  clinical trial of nicotine vaccine for smoking cessation and relapse prevention source text for eikon further company coverage selecta biosciences announces first quarter  financial results and provides corporate update globenewswire –  pm et  watertown mass may    selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today reported financial results for the first quarter ended march   and provided a corporate update selecta biosciences commences dosing in phase  clinical trial of nicotine vaccine for smoking cessation and relapse prevention globenewswire –  pm et  selecta biosciences inc selb today announced that patient dosing has commenced in a phase  clinical trial to assess the safety tolerability and pharmacodynamic profile of sela a nicotine vaccine candidate in development for smoking cessation and relapse prevention selecta biosciences to report first quarter  financial results on thursday may   globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced that it plans to issue its first quarter  financial results after the markets close on thursday may   briefselecta biosciences obtains license for recombinant immunotoxin lmb from national cancer institute reuters –  am et  selecta biosciences inc selb  selecta biosciences obtains license for recombinant immunotoxin lmb from national cancer institute for pancreatic cancer mesothelioma and other cancers  selecta biosciences inc selb  under terms of license agreement nci will receive an upfront payment of  from selecta selecta biosciences obtains license for recombinant immunotoxin lmb from national cancer institute nci for pancreatic cancer mesothelioma and other cancers globenewswire –  am et  watertown mass may     selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced that it has licensed lmb a nextgeneration immunotoxin from the center for cancer research at the nci part of the national institutes of health selecta biosciences announces presentations at the th annual meeting of the american society of gene  cell therapy globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on developing biologic therapies that avoid unwanted immunogenicity for the treatment of rare and serious diseases today announced several presentations at the th annual meeting of the american society of gene  cell therapy taking place may   at the marriott wardman park hotel in washington dc select selecta biosciences to present at two upcoming investor conferences in may globenewswire –  am et  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on developing biologic therapies for rare and serious diseases that avoid unwanted immunogenicity today announced that president ceo and chairman werner cautreels phd will present at the following investor conferences in may live and archived webcasts of the presentations will be available on the investors  me page page   next  todays and upcoming events aug  selb to announce q earnings before market unconfirmed past events last  days jun  shareholders meeting data provided by wall street horizon inc   technical events classic patterns past  days provided by recognia inc log in for trading events view all technical analysis in advanced chart technical analysis provided by trading central log in for trading events as with all your investments through fidelity you must make your own determination whether an investment is appropriate for you fidelity is not recommending or endorsing this security by making it available to customers you should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase before investing you should read the prospectus offering circular indenture or similar document carefully for a full description of the product including its features and risks to determine whether it is an appropriate investment for your investment objectives risk tolerance financial situation and other individual factors and be sure to reevaluate those factors on a periodic basisperformance data shown represents past performance which is no guarantee of future results current performance may be higher or lower than the performance data quoted yield and return will vary therefore you may have a gain or loss when you sell your sharesstock markets are volatile and can decline significantly in response to adverse issuer political regulatory market or economic developments growth stocks can be more volatile than other types of stocks value stocks can continue to be undervalued by the market for long periods of time foreign securities are subject to interestrate currencyexchangerate economic and political risks all of which are magnified in emerging markets illiquidity is an inherent risk associated with investing in real estate and reits there is no guarantee the issuer of a reit will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid closedend funds can trade at a discount to their nav shareholders of master limited partnerships may be treated as partners for tax purposes partnerships issue a schedule k form  rather than a form  form for tax purposes it lists the partners share of income deductions credits etc speak with your tax advisor to determine how this may affect you a royalty trust is a type of corporation mostly in the united states or canada usually involved in oil and gas production or mining royalty trusts may have special tax treatment so you should consult a tax advisor on the potential tax consequences of investing in themnews commentary and events are from thirdparty sources unaffiliated with fidelity fidelity does not endorse or adopt their content fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from their useany data charts and other information provided on this page are intended for research purposes to help selfdirected investors evaluate many types of securities including but not limited to common stocks american depository receipts master limited partnerships real estate investment trusts traditional preferred stock trust preferred securities thirdparty trust certificates convertible securities mandatory convertible securities and other exchangetraded equity andor debt securities criteria and inputs entered including the choice to make security comparisons are at the sole discretion of the user and are solely for the convenience of the user analyst opinions ratings and reports are provided by thirdparties unaffiliated with fidelity all information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance an offer of or a solicitation of an offer to buy or sell a security or a recommendation or endorsement by fidelity of any security or investment strategy fidelity does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating individual securities fidelity makes no guarantees that information supplied is accurate complete or timely and does not provide any warranties regarding results obtained from its use copyright – fmr llc  all rights reserved  terms of use privacy security site map  see the latest features personalizedget relevant information about your holdings right when you need itsee your performance click the portfolio icon to get information about stocks you own without leaving the research pagefaster access to positions a shortcut to view the full list of positions in your portfolio yes please use the ticker search boxadd your own notes use notebook to save your investment ideas in one convenient private and secure place convenient for youresearch thats clear accessible and all in one place makes for a better experienceonestop shop see everything you need to make investment decisions right in the dashboardaccess anywhere no matter where you are use the stock research experience across multiple devicesnew ideas on the ready find new ideas using quick links to the stock screener new ways to researchdiscover new tools to add or diversify your existing research strategystocktwits read live tweets from the financial and investing community about the stock youre interested infundamental analysis save time on research by getting an overall assessment of a companys valuation quality growth stability and financial healthrecognia technical analysis perfect for the technical trader—this indicator captures a stocks technical events and converts them into short medium and longterm sentimenttop competitors see how a stock measures up by instantly comparing it to the industry average and its top four competitorssocial sentiment get a sense of peoples overall feelings towards a company in social media with this summary toolearnings data monitor earnings expectations over the past three quarters and model a stocks price based on its pe selecta biosciences announces addition of patrick j zenner to board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street selecta biosciences announces addition of patrick j zenner to board of directors globenewswire jun    am edt watertown mass june   globe newswire  selecta biosciences inc nasdaqselb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the election of patrick j zenner to its board of directors at the companys  annual meeting of stockholders which was held on june   mr zenner previously served as president and chief executive officer of hoffmannla roche inc north america the prescription drug unit of roche i am delighted that we were able to add an executive of patricks caliber to selectas board of directors said werner cautreels phd ceo and chairman of selecta we believe his experience in leading an expanding organization navigating regulatory hurdles and commercializing a range of major therapeutics will be key as we seek to advance our clinical programs and enable new treatments using our synthetic vaccine particles svp™ technology platform prior to his retirement mr zenner held various positions during his year career at roche he currently serves as chairman of the boards of directors of both arqule inc and west pharmaceutical services inc previously mr zenner served as a director of par pharmaceuticals and several other public and private company boards he received his bsba from creighton university and his mba from fairleigh dickinson university about selecta biosciences incselecta biosciences inc is a clinicalstage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses selecta plans to combine its tolerogenic synthetic vaccine particles svp™ to a range of biologics for rare and serious diseases that require new treatment options the companys current proprietary pipeline includes svpenabled enzyme oncology and gene therapies sel the companys lead candidate in phase  is being developed to treat severe gout patients and resolve their debilitating symptoms including flares and gouty arthritis selectas clinical oncology candidate lmb is in a phase  program targeting pancreatic cancer and mesothelioma its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration the use of svp is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases selecta is based in watertown massachusetts for more information please visit httpselectabiocom and follow selectabio on twitter trending ftc seen as set to block rite aid deal the  absolutely cheapest places to buy a house in america it would be crazy to clean house at wells fargo ceo says tesla ceo elon musk we are going to be in production hell for  months advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers selecta biosciences announces addition of patrick j zenner to board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets closedsp  dow  nasdaq listenwho is the face of pro baseballyahoo finances dan roberts and myles udland debate the business of baseballselecta biosciences announces addition of patrick j zenner to board of directorsglobenewswire•june  reblogsharetweetsharewatertown mass june   globe newswire  selecta biosciences inc selb a clinicalstage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses today announced the election of patrick j zenner to its board of directors at the company’s  annual meeting of stockholders which was held on june   mr zenner previously served as president and chief executive officer of hoffmannla roche inc north america the prescription drug unit of roche“i am delighted that we were able to add an executive of patrick’s caliber to selecta’s board of directors” said werner cautreels phd ceo and chairman of selecta “we believe his experience in leading an expanding organization navigating regulatory hurdles and commercializing a range of major therapeutics will be key as we seek to advance our clinical programs and enable new treatments using our synthetic vaccine particles svp™ technology platform”prior to his retirement mr zenner held various positions during his year career at roche he currently serves as chairman of the boards of directors of both arqule inc and west pharmaceutical services inc previously mr zenner served as a director of par pharmaceuticals and several other public and private company boards he received his bsba from creighton university and his mba from fairleigh dickinson universityabout selecta biosciences incselecta biosciences inc is a clinicalstage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by avoiding unwanted immune responses selecta plans to combine its tolerogenic synthetic vaccine particles svp™ to a range of biologics for rare and serious diseases that require new treatment options the company’s current proprietary pipeline includes svpenabled enzyme oncology and gene therapies sel the company’s lead candidate in phase  is being developed to treat severe gout patients and resolve their debilitating symptoms including flares and gouty arthritis selecta’s clinical oncology candidate lmb is in a phase  program targeting pancreatic cancer and mesothelioma its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration the use of svp is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases selecta is based in watertown massachusetts for more information please visit httpselectabiocom and follow selectabio on twitterforwardlooking statements any statements in this press release about the future expectations plans and prospects of selecta biosciences inc “the company” including without limitation the company’s ability to unlock the full potential of biologic therapies the company’s plan to apply its svp platform to a range of biologics for rare and serious diseases the potential of sel to treat severe gout patients and resolve their debilitating symptoms the potential of the company’s two gene therapy product candidates to enable repeat administration the potential treatment applications for products utilizing the svp platform in areas such as gene therapy immunooncology allergies autoimmune diseases and vaccines and other statements containing the words “anticipate” “believe” “continue” “could” “estimate” “expect” “hypothesize” “intend” “may” “plan” “potential” “predict” “project” “should” “target” “would” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors discussed in the “risk factors” section of the company’s quarterly report on form q filed with the securities and exchange commission or sec on may   and in other filings that the company makes with the sec in addition any forwardlooking statements included in this press release represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date the company specifically disclaims any obligation to update any forwardlooking statements included in this press releaseread morereblogsharetweetsharerecently viewedyour list is emptywhat to read nexttrump divorce former nfl cheerleader and florida state attorney split over us presidentthe telegraphthis will be in everyones household by banyan hillsponsoredamazons alexa boss says the ultimate goal is to reinvent the star trek computerbusiness insiderfox ups jonathan gabay to svp comedy development  programmingdeadlineanthony scaramuccis wife reportedly filed for divorce because he was hellbent on joining trumpbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredmainstream model  holds promise  and peril  for teslaassociated pressthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderchevron and exxon mobil have a tough path ahead nyse traderyahoo finance videodiscover it  out of  avg by k customersdiscover cardsponsoredstocks mixed after heavy earnings weekthe real reason overseas manufacturing is coming to americayahoo financetrump to cops please dont be too nice while arresting thugs and dont worry about their heads when you toss them in the paddy wagonbusiness insidercardiologist  foods you should quit immediatelygundry mdsponsoredchrissy teigen is ‘so happy’ donald trump blocked her on twitterfortunemy bullish view on stocks hasnt changed one iota nyse traderyahoo finance videochrissy teigen is ‘so happy’ donald trump blocked her on twitterking kong this girl is an ugly mut  id block her if i was on twitter too join the conversation